- Home
- CNTB vs KZR Comparison
CNTB vs KZR Comparison
Compare CNTB & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- KZR
- Stock Information
- Founded
- CNTB 2012
- KZR 2015
- Country
- CNTB United States
- KZR United States
- Employees
- CNTB N/A
- KZR N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- KZR Health Care
- Exchange
- CNTB Nasdaq
- KZR Nasdaq
- Market Cap
- CNTB 65.5M
- KZR 54.1M
- IPO Year
- CNTB 2021
- KZR 2018
- Fundamental
- Price
- CNTB $1.06
- KZR $6.41
- Analyst Decision
- CNTB Strong Buy
- KZR Hold
- Analyst Count
- CNTB 1
- KZR 2
- Target Price
- CNTB $8.00
- KZR $11.00
- AVG Volume (30 Days)
- CNTB 31.2K
- KZR 61.0K
- Earning Date
- CNTB 09-05-2024
- KZR 11-12-2024
- Dividend Yield
- CNTB N/A
- KZR N/A
- EPS Growth
- CNTB N/A
- KZR N/A
- EPS
- CNTB N/A
- KZR N/A
- Revenue
- CNTB $24,116,000.00
- KZR N/A
- Revenue This Year
- CNTB N/A
- KZR N/A
- Revenue Next Year
- CNTB $63.90
- KZR N/A
- P/E Ratio
- CNTB N/A
- KZR N/A
- Revenue Growth
- CNTB N/A
- KZR N/A
- 52 Week Low
- CNTB $0.77
- KZR $5.20
- 52 Week High
- CNTB $2.66
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- CNTB 46.58
- KZR 28.75
- Support Level
- CNTB $1.04
- KZR $6.80
- Resistance Level
- CNTB $1.23
- KZR $7.04
- Average True Range (ATR)
- CNTB 0.10
- KZR 0.24
- MACD
- CNTB 0.01
- KZR -0.06
- Stochastic Oscillator
- CNTB 42.37
- KZR 0.00
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.